← 返回

外周血来源自体 NK 细胞的纯化及无抗体离体扩增:一项关于患者安全性和耐受性的马来西亚病例系列

英文原题:Purification and antibody-free ex-vivo expansion of peripheral blood-derived autologous natural killer cells: A Malaysian case series on patient safety and tolerability.

查看英文原题

Purification and antibody-free ex-vivo expansion of peripheral blood-derived autologous natural killer cells: A Malaysian case series on patient safety and tolerability.

PubMed 2026/02/21(内容时间) SAGE Open Med Case Rep Q3 · IF 0.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

NK 细胞是免疫治疗中研究和使用最多的细胞,已从自体免疫增强疗法扩展到基因增强细胞疗法,如嵌合抗原受体NK 细胞。本临床病例研究旨在分析和评估通过内部开发的培养方案体外扩增的自体NK 细胞的安全性和耐受性。这一新型培养方案能够获得高产量、高纯度的NK 细胞批次,无需使用抗体、无需预先进行NK 细胞纯化,也无需任何磁珠标记,从而实现完全人源兼容的细胞扩增过程。在本报告中,共有九名患者接受了内部培养的NK 细胞的临床输注,并在输注前后监测血液学参数、肝功能谱、超敏反应、炎症标志物以及肿瘤前期标志物,以评估NK 细胞诱导或任何剂量依赖性毒性/不良反应的可能性。

结果表明,接受NK 细胞输注的患者表现出良好的临床安全性,没有肝毒性、超敏反应、炎症或任何初步肿瘤标志物波动的迹象。该研究为马来西亚患者通过内部方案培养的自体来源NK 细胞的临床耐受性提供了支持性证据,并为未来在更广泛患者群体中开展的临床研究奠定了基础。

展开英文摘要原文

Natural killer cells are the most researched and employed cells for immunotherapy, which have expanded from autologous immune-enhanced therapies to genetically enhanced cell therapies such as chimeric antigen receptors natural killer cells. The present clinical case study aims to analyze and evaluate the safety and tolerability of ex-vivo expanded autologous natural killer cells via an in-house developed culture protocol. The novel, cultivation protocol enables high-yield and pure natural killer cell batches free of antibody usage, prior natural killer cell purification, or any magnetic-bead labeling, resulting in a fully human compatible cell expansion process.

In this report, a total of nine patients were clinically infused with the in-house cultured natural killer cells and were monitored pre- and postinfusion for haematological parameters, liver function profile, hypersensitivity, inflammatory markers as well as pretumor markers to assess for the possibilities of natural killer cell-induced or any dose-dependent toxic/adverse reactions.

The outcomes indicate that the patient infused with natural killer cells demonstrates good level of clinical safety with no signs of hepatotoxicity, hypersensitivity, inflammation, or any flares of preliminary tumor markers. The study provides supportive evidence of the clinical tolerance of autologous-derived natural killer cells cultured via the in-house protocol on patients in Malaysia and establishes a baseline for future clinical studies with a wider range of patients.

论文信息

作者
Thevendran R、Ravichandran M、Tham SK
单位
Celestialab Sdn. Bhd., Kuala Lumpur, Malaysia.Malaysia
文献类型
病例报告
期刊
SAGE open medical case reports2026
原文标识
PubMed 41732589 · DOI 10.1177/2050313X251376950